《盈利預喜》安莉芳(01388.HK)料中期淨利潤約500萬元
安莉芳控股(01388.HK)發盈喜,截至2023年6月30日止六個月,預計錄得淨利潤爲約500萬元,上年同期淨利潤爲111.6萬元。增長主要歸因於其他費用減少,特別是集團先前已確認的使用權資產減值的回撥;及集團確認稅收抵免。
另外,於今年4月至6月期間,集團整體銷與去年同期基本持平,主要由於第二季度人民幣貶值,而按固定匯率計算,大陸市場銷售額較去年同期增長約5%。第二季度期間,經營逾18個月的店鋪中,同店銷售錄得單位數的按年跌幅。
截至6月底,集團總零售點爲1,039個,其中銷售專櫃及專門店數目分別爲872個及167個。集團的零售點數目較去年12月底淨減少45個。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.